Kornimate/medical-research-clean huggingface dataset:
total hemihepatic vascular exclusion in hepatectomy in hepatocellular carcinoma treatment

Conditions: Hepatocellular Carcinoma

Summary: total hemihepatic vascular exclusion(thhve),completely isolates the right or left hemiliver ipsilateral to the lesion that requires resection from the systemic circulation,has the advantage of preventing backflow hemorrhage or air embolism without having to resort to caval blood flow interruption of thve.this study is to evaluate if thhve can raduce bleeding,reduce the incidence of complications and improve the patient's free survival and overall survival compared with hemihepatic vascular clamping and pringle maneuver.

the amount of blood loss and blood transfusion in hepatectomy have a detrimental effect on the prognosis for hepatocellular carcinoma(hcc).intraoperative bleeding remains a major concern during liver resection. the most often used hepatic vascular control methods at present are hepatic pedicle occlusion(pringle maneuver), hemihepatic vascular clamping,segmental vascular clamping and total hepatic vascular exclusion (thve).however,all these methods have shortcomings. pringle maneuver cannot prevent bleeding from hepatic veins and leads to ischemia-reperfusion injury of the liver; hemihepatic vascular clamping cannot prevent bleeding from hepatic veins as well, and from the remnant (nonoccluded) liver. thve is a technically demanding technique that requires surgical and anesthetic expertise and may lead to hemodynamic intolerance as well as increased morbidity and hospital stay. total hemihepatic vascular exclusion(thhve),completely isolates the right or left hemiliver ipsilateral to the lesion that requires resection from the systemic circulation,has the advantage of preventing backflow hemorrhage or air embolism without having to resort to caval blood flow interruption of thve. the purpose of this study is to evaluate if thhve can raduce bleeding,reduce the incidence of complications and improve the patient's free survival and overall survival compared with other occlusion methods.

Eligibility criteria:
5inclusion criteria: * understanding and being willing to sigh the informed consent form. * aged 18-75years. * corresponding to diagnostic standards of hcc, without any adjuvant therapy,tumor or multiple tumors located in right or left liver lobe. * the function of heart, lung ,renal is well,without any surgery contraindication. * kps score≥60分 * liver function in the child-pugh classification is a or b. * tumor ajcc stage isⅰorⅱ. exclusion criteria: * cannot be follow-up * liver function in the child-pugh classification is c. * with tumor thrombus in the hepatic vein or main trunk of portal vein * with extrahepatic metastasis

Keywords: hepatocellular carcinoma surgical resection total hemihepatic vascular exclusion occlusion bleeding overall survival
rehabilitation in multiple sclerosis - sometimes too much?

Conditions: Multiple Sclerosis

Summary: the primary objective is to evaluate changes in fatigue and physical activity (step counts) before and after rehabilitation in patients with ms (edss 3-6.5). the association of changes in fatigue and physical activity will also be analyzed for disease severity (edss), age, emotional status (depression) of the participants.

around 2 million people worldwide have multiple sclerosis (ms) and it is the most common neurological disease in young adults. the greatest incidence of ms is found in europe (108 per 100'000). over 50% of the patients with ms suffer from fatigue and reduced physical activity. the association between inactivity and fatigue is low in patients with mild disability. rehabilitation in valens includes intensive strength and endurance training. endurance and walking improve in most patients, evaluated during rehabilitation with the timed-up and go (tug) and 2 minute walking tests (2mwt). however, clinic valens occasionally gets feedback from physical therapists in the ambulatory setting, that outcome after rehabilitation is sometimes poor and some patients with ms (pwms) seem to be over trained, less mobile, more fatigued and need to recover for several weeks. physical therapists in valens know that training is fatiguing. if they knew how many, and which patients are more fatigued and less active after rehabilitation they could reduce treatment intensity and prevent overtraining. to the knowledge of the investigators no study evaluated changes after rehabilitation in fatigue, assessed with a disease specific questionnaire (fsmc), and mobility at home using accelerometers. potential predictors of poor outcome are disease severity (edss), pre-rehabilitation fatigue and depression. the primary goal of this study therefore is to evaluate changes in fatigue and physical activity (step counts) in pwms assessed before rehabilitation, after rehabilitation and at 2 months follow-up.

Eligibility criteria:
inclusion criteria: * edss 3-6.5, an edss 6.5 means the ability to walk 20 meters without resting, using constant bilateral assistance * \>18 years old * german speaking * good function of the upper extremity to put on actigraph by themselves * participants should be able to wear the actigraph at least 6h/day for 7 days exclusion criteria: * inability to follow the instructions given, e.g. language problems, psychological disorders * no informed consent

Keywords: physical activity fatigue rehabilitation
arthroscopic surgical outcome study in subjects with rotator cuff tears

Conditions: Rotator Cuff; Arthroscopic Surgery

Summary: this is an observational study that involves subjects with full-thickness rotator cuff tears treated by means of arthroscopy surgical repair, also known as arthroscopic surgery. the primary objective of this study is to observe the timing and rate of tendon retear in those subjects.

subjects will be recruited from each surgeon's surgical practice. they will be reviewed to assure they meet all eligibility criteria prior to enrolling them into the study.

Eligibility criteria:
inclusion criteria: * full thickness rotator cuff tears ranging from 1cm to 4cm in size. * planned procedure for repair is tendon-to-bone repair by means of an arthroscopy exclusion criteria: * previous surgical intervention to the shoulder joint understudy * tears of the subscapularis or labral pathology requiring surgical repair * shoulder instability either shoulder * unable to complete functional evaluations in either shoulder

Keywords: observational rotator cuff tear arthroscopic surgical outcome study
tolerance of early postoperative mobilization and ambulation

Conditions: Ambulation Difficulty; Colorectal Surgery; Bariatric Surgery

Summary: enhanced recovery programme (erp) includes early postoperative mobilization and ambulation the day of surgery. data suggest that orthostatic symptoms prevent a large number of patients from ambulating the day of surgery. the investigators plan to include 50 patients scheduled for colorectal surgery and bariatric surgery in an erp. a 6-min walk test (6mwt) will be performed before surgery, 3 hour after the end of surgery, and 24 hour after surgery. the day of surgery a 2-min walk test will be realized.

enhanced recovery programme (erp) includes early postoperative mobilization and ambulation the day of surgery. data suggest that orthostatic symptoms prevent a large number of patients (up to 50%) from ambulating the day of surgery. the investigators plan to include 50 patients scheduled for colorectal surgery and bariatric surgery in an erp. the primary endpoint will be the ability to get out of the bed and sit in an armchair. orthostatic symptom will be recorded. the secondary endpoint will be a 6-min walk test (6-mwt). this test will be performed before surgery, 3 hour after the end of surgery, and 24 hour after surgery. the day of surgery a 2-min walk test (2-mwt) will be realized. correlation of the ability to early ambulate and postoperative course (adherence to erp, complications) will be analyzed.

Eligibility criteria:
inclusion criteria: patients scheduled for colorectal or bariatric surgery within an erp exclusion criteria: patient refusal to participate, inability to walk or stand up.
effectiveness of therapy with a thermal water nasal aerosol in children with seasonal allergic rhinitis

Conditions: Allergic Rhinitis (Disorder)

Summary: the purpose of this study was to evaluate the effects of ischia thermal waters nasal irrigation on allergic rhinitis and airway inflammation during the period of natural exposure to parietaria pollen in children with allergic rhinitis and intermittent asthma.

the study was conducted on the island of ischia - naples from april to june 2009, during the natural exposure period to parietaria pollen. the treatment started just before the pollen season, when all the children were asymptomatic, not treated with any drug and not affected by respiratory tract and systemic diseases. all the children were randomly divided into two homogeneous groups by sex and age. the first group has practiced crenotherapy with "hyper-mineral chloride sodium water" aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of lacco ameno, while the control group was treated, in the same period, daily, by a micronized nasal douche with 0.9% nacl (isotonic) solution. before the treatment (t0), at the end of the treatment (t1) and again 2 weeks after the end of the treatment (t2), all the children have performed spirometry (pony fx cosmed), and exhaled nitric oxide (feno) (niox mino analyzer cosmed), to assess their airway inflammation. at the time of recruitment, the parents of the children were instructed to fill a specific diary-card (tss) at home, to assess rhinitis symptoms and possible drug use during all 3 months of treatment. the parameters considered in the tss were: nasal obstruction, sneezing, nasal discharge and itching. these symptoms were scored: 0 = symptom absent, 1 = mild (symptoms present but not annoying), 2 = moderate (frequent and offensive symptoms but do not interfere with sleep or normal activities) 3 = severe (symptoms that interfere with sleep or normal activities). every two weeks, at the end of each cycle of therapy the children underwent a general clinical control with nasal endoscopy, spirometry and monitoring the completion of diary cards and the possible use of drugs.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of moderate to severe allergic rhinitis. * children aged 6-14 year sensitized to parietaria. * history of spring time symptoms. * history of mild intermittent asthma. exclusion criteria: * use of laba, antihistamines, intranasal, bronchial or systemic corticosteroids, cromolyn sodium and leukotriene modifiers in the last 6 weeks. * the presence of respiratory tract infection, persistent asthma, respiratory tract abnormalities or diseases.
a long-term observational study to describe the use of vitamin-c injektopas® 7.5 g in patients with vitamin c deficiency

Conditions: Deficiency, Vitamin C; Chronic Disease; Acute Disease

Summary: the goal of this observational study is to learn more about the disease and the symptoms where the product will use and in which patient groups. further on, it is interesting to know clinical pictures, the symptoms improve. patients with acute or chronical disease with vitamin c deficiency could be involved. the main questions it aims to answer are: * how do the symptoms of the disease change * how is the tolerability

the aim of this long-term observational study is to document the use of vitamin c injektopas® 7.5g in patients with vitamin c deficiency. the deficiency condition can be diagnosed either by laboratory diagnosis or clinically, i.e. symptomatically on the basis of general vitamin c deficiency symptoms (e.g. weakness, fatigue, susceptibility to infections and psychological complaints such as depressive moods) through to more specific deficiency symptoms, which are primarily related to impaired collagen formation and therefore primarily affect connective tissue, blood vessels, cartilage and bones. these include, above all, haemorrhages in the skin, inflamed and bleeding gums - through to tooth loss, joint effusions, pain in the joints, bones and muscles as well as poorly healing wounds, etc. the survey should be used to assess the disease underlying the vitamin c deficiency (the so-called underlying disease), the reduction in the symptoms of the disease under therapy and also the tolerability. both acute and chronic underlying diseases should be taken into account. in addition to the symptom enquiry, the global assessment of the efficacy and tolerability of therapy with vitamin c injektopas® 7.5g is evaluated.

Eligibility criteria:
inclusion criteria: * patients with vitamin c deficiency * age ≥ 18 years exclusion criteria: * hypersensitivity to the active ingredient or any of the excipients * oxalate urolithiasis * iron storage disease (thalassemia, hemochromatosis, sideroblastic anemia) or recent red blood cell transfusion * renal insufficiency * glucose-6-phosphate dehydrogenase deficiency/defect * pregnant/breastfeeding women
use of tens in non-surgical periodontal treatment

Conditions: Non-surgical Periodontal Therapy

Summary: the aim of the study is to verify the use of tens in non-surgical periodontal therapy in order to relief pain

non-surgical periodontal therapy could be painfull for some patients and the pain that they may experience can let them avoid therapies, with huge risks for their oral health. transcutaneous electrical neurostimulation (tens) is a device largely used in temporomandibular disorders in order to reduce pain. the aim of our study is to analyze the effect of transcutaneous electrical neurostimulation (tens) at the tragus during non-surgical periodontal therapy fro pain relief

Eligibility criteria:
inclusion criteria: * patients aging more than 18 and of both sexes seeking for non-surgical periodontal treatment exclusion criteria: * patients following opioids or analgesic therapies during the study * pregnant women * patients who have had episodes of epilepsy * pace-maker patients * patients who did not signed the informed consent to participate in the study.

Keywords: ulf-tens pain non-surgical periodontal therapy scaling
vinorelbine and/or gemcitabine in treating older patients with stage iiib or stage iv non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: randomized phase iii trial to compare the effectiveness of vinorelbine, gemcitabine, or both in treating patients who have stage iiib or stage iv non-small cell lung cancer.

objectives: i. determine the activity and toxicities of gemcitabine in elderly patients with non-small cell lung cancer. ii. determine the activity and toxicity of the combination of gemcitabine and vinorelbine in these patients. iii. compare the survival rate and quality of life of these patients treated with combination chemotherapy versus single agent chemotherapy. iv. compare objective response and time to progression of these patients treated with these chemotherapy regimens. v. compare the toxicities of these three regimens in these patients. vi. compare the number of hospitalizations, palliative radiation therapies, antibiotic therapies, corticosteroid therapies, analgesic therapies, and hematopoietic growth factor therapies needed for these patients treated with these chemotherapy regimens. outline: this is a randomized, multicenter study. patients are stratified by center, stage of disease (iiib vs iv), and performance status (0 vs 1 vs 2). patients are randomized to one of three treatment arms. patients receive either vinorelbine iv, gemcitabine iv, or both on days 1 and 8 of each 21 day course. patients who achieve an objective response or stable disease after 3 courses receive 3 more courses (for a total of 6 courses). quality of life is assessed before treatment, after course 4 (or 3 weeks after course 3, if therapy is stopped), and at 21 days after course 6 (or 12 weeks after course 3). projected accrual: a total of 630 patients (210 patients per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically proven non-small cell lung cancer stage iv or stage iiib that has supraclavicular lymph node metastases or has pleural deposits and is not curable with surgery or radical radiotherapy no brain metastases suspected clinically or demonstrated radiologically patient characteristics: age: 70 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: neutrophil count at least 2000/mm3 platelet count at least 100,000/mm3 hemoglobin at least 10 g/dl hepatic: (unless caused by tumor) bilirubin no greater than 1.25 times upper limit of normal (uln) sgot or sgpt no greater than 1.25 times uln renal: creatinine no greater than 1.5 mg/dl other: no other serious medical illness no prior or concurrent malignancy except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix prior concurrent therapy: no prior chemotherapy

Keywords: stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
hepatitis c-video vs. brochure education delivery

Conditions: Hepatitis C

Summary: the purpose of this study is to determine the most effective way to give patients information regarding hepatitis c virus infection. the investigators plan to compare the information retained by some patients who are given a brochure alone versus patients who watch an interactive video about hepatitis c.

subjects will complete 3 questionnaires, including one about knowledge of hepatitis c. the subject will then either watch a video or read a brochure about hepatitis c, then take the same questionnaire again. the subject will then return in one month to take the hepatitis c questionnaire again.

Eligibility criteria:
inclusion criteria: * currently on active treatment for opioid addiction/use * english as primary language exclusion criteria: -
safety and efficacy of product 33525 (luliconazole cream 1%) in pediatric participants with tinea corporis

Conditions: Tinea Corporis

Summary: the objective of this study was to evaluate the safety, efficacy, and pharmacokinetics of luliconazole cream 1% when applied topically for 7 days in pediatric participants 2 years to 17 years of age (inclusive) with tinea corporis.


Eligibility criteria:
key inclusion criteria: * participants (or legal guardian/caregiver) with the ability and willingness to sign a written informed consent and/or assent (age appropriate). * participants of either gender must be at least 2 years to less than (\<) 18 years of age (2 to 17 years, inclusive). * participants with a clinical diagnosis of tinea corporis characterized by clinical evidence of a tinea infection (at least moderate erythema, mild scaling, and moderate pruritus). * participants must be in good general health and free of any disease that in the investigator's opinion might interfere with the study evaluations. * participants/caregiver must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements. key exclusion criteria: * participants with active atopic or contact dermatitis in the area to be treated. * participants with severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection. * female participants who are pregnant and/or nursing or planning a pregnancy during the course of the trial. participants who test positive for pregnancy after start study drug will be discontinued from study drug but will be followed for safety purposes. * participants who are immunocompromised (due to disease, for example; human immunodeficiency virus \[hiv\] or medications). * participants who have a recent history of or current drug or alcohol abuse.
phase 2 study of autologous followed by nonmyeloablative allogeneic transplantation using tli & atg

Conditions: Transplantation, Homologous; Transplantation, Autologous; Multiple Myeloma; Blood and Marrow Transplant (BMT)

Summary: to evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.

development of cell-based immunotherapy from allogeneic hematopoietic cell transplantation (hct) is dependent upon stable t-cell engraftment and the success of this therapeutic approach is likely to be greatest when directed against a minimal rather than gross tumor burden. to this end, tandem transplants with high dose therapy and autologous hematopoietic cell transplantation (ahct) for tumor cytoreduction followed by non-myeloablative allotransplant have been conducted. in myeloma, this tandem approach results in greater efficacy compared to conventional ahct.

Eligibility criteria:
participant inclusion criteria * stage ii-iii multiple myeloma or have progression after initial treatment of stage i disease (durie salmon staging). patients with plasma cell leukemia are also included. * multiple myeloma / plasma cell leukemia diagnosis confirmed by pathology reviewed at stanford university medical center. * 18 to ≤ 75 years of age * karnofsky performance status \> 70%. * corrected carbon monoxide diffusing capacity (dlco) \> 60% * left ventricle ejection fraction (lvef) \> 50%. * alanine aminotransferase (alt) ≤ 2 x normal * aspartate aminotransferase (ast) ≤ 2 x normal * total bilirubin ≤ 2 mg/dl, unless hemolysis or gilbert's disease. * estimated creatinine clearance \> 50 ml/min. * identified related or unrelated human leukocyte antigen (hla)-identical donor or donor with one antigen/allele mismatch in (hla-a, b, c or drb1). * signed informed consent. donor inclusion criteria * at least 17 years of age * hiv-seronegative * must be capable of giving signed, informed consent * no contraindication to the administration of filgrastim * willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate participant exclusion criteria * prior allogeneic hematopoietic cell transplantation * uncontrolled active infection * uncontrolled congestive heart failure or angina * hiv-positive * pregnant or nursing donor exclusion criteria * serious medical or psychological illness * pregnant or lactating * prior malignancies within the last 5 years except for non-melanoma skin cancers